101,569 Shares in Labcorp Holdings Inc. $LH Acquired by Strs Ohio

13 Sep 2025, 10:31 by Tristan Rich · The Markets Daily

Strs Ohio acquired a new position in Labcorp Holdings Inc. (NYSE:LH – Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 101,569 shares of the medical research company’s stock, valued at approximately $23,639,000. Strs Ohio owned about 0.12% of Labcorp at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Dynamic Technology Lab Private Ltd bought a new stake in Labcorp during the 1st quarter worth approximately $2,639,000. Teewinot Capital Advisers L.L.C. bought a new stake in Labcorp during the 1st quarter worth approximately $709,000. AQR Capital Management LLC raised its stake in Labcorp by 8.1% during the 1st quarter. AQR Capital Management LLC now owns 163,798 shares of the medical research company’s stock worth $37,762,000 after acquiring an additional 12,281 shares during the period. Brighton Jones LLC bought a new stake in Labcorp during the 4th quarter worth approximately $991,000. Finally, Wealth Enhancement Advisory Services LLC raised its stake in Labcorp by 84.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 36,182 shares of the medical research company’s stock worth $8,421,000 after acquiring an additional 16,574 shares during the period. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Insider Buying and Selling at Labcorp

In related news, Director Dwight Gary Gilliland sold 2,000 shares of the business’s stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $264.95, for a total value of $529,900.00. Following the sale, the director owned 6,656 shares in the company, valued at approximately $1,763,507.20. The trade was a 23.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Der Vaart Sandra D. Van sold 3,903 shares of the business’s stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $271.42, for a total transaction of $1,059,352.26. Following the completion of the sale, the executive vice president owned 2,274 shares in the company, valued at $617,209.08. This represents a 63.19% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 15,546 shares of company stock worth $4,207,192. Company insiders own 0.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on LH. HSBC cut shares of Labcorp from a “buy” rating to a “hold” rating and set a $260.00 target price on the stock. in a research note on Thursday, July 10th. UBS Group raised their target price on shares of Labcorp from $282.00 to $305.00 and gave the stock a “buy” rating in a research note on Friday, July 25th. Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Barclays restated a “cautious” rating on shares of Labcorp in a research note on Wednesday, June 25th. Finally, Morgan Stanley lifted their price objective on shares of Labcorp from $283.00 to $306.00 and gave the company an “overweight” rating in a research report on Friday, July 25th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Labcorp presently has a consensus rating of “Moderate Buy” and an average target price of $290.33.

Check Out Our Latest Stock Analysis on LH

Labcorp Price Performance

LH stock opened at $278.06 on Friday. Labcorp Holdings Inc. has a one year low of $209.38 and a one year high of $283.47. The company’s fifty day moving average price is $265.85 and its 200-day moving average price is $251.12. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.32 and a current ratio of 1.50. The company has a market capitalization of $23.11 billion, a PE ratio of 30.69, a price-to-earnings-growth ratio of 1.79 and a beta of 0.85.

Labcorp (NYSE:LH – Get Free Report) last released its earnings results on Thursday, July 24th. The medical research company reported $4.35 EPS for the quarter, topping the consensus estimate of $4.14 by $0.21. Labcorp had a net margin of 5.66% and a return on equity of 15.45%. The firm had revenue of $3.53 billion for the quarter, compared to the consensus estimate of $3.49 billion. During the same quarter in the previous year, the firm earned $3.94 earnings per share. The company’s quarterly revenue was up 9.6% compared to the same quarter last year. Labcorp has set its FY 2025 guidance at 16.050-16.500 EPS. On average, equities analysts anticipate that Labcorp Holdings Inc. will post 16.01 EPS for the current fiscal year.

Labcorp Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 11th. Investors of record on Thursday, August 28th were given a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 1.0%. The ex-dividend date was Thursday, August 28th. Labcorp’s payout ratio is currently 31.79%.

Labcorp Profile

(Free Report)